IL219372A0 - Bicyclic pyridines and analogs as sirtuin modulators - Google Patents

Bicyclic pyridines and analogs as sirtuin modulators

Info

Publication number
IL219372A0
IL219372A0 IL219372A IL21937212A IL219372A0 IL 219372 A0 IL219372 A0 IL 219372A0 IL 219372 A IL219372 A IL 219372A IL 21937212 A IL21937212 A IL 21937212A IL 219372 A0 IL219372 A0 IL 219372A0
Authority
IL
Israel
Prior art keywords
analogs
sirtuin modulators
pyridines
bicyclic
bicyclic pyridines
Prior art date
Application number
IL219372A
Other languages
English (en)
Original Assignee
Sirtris Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sirtris Pharmaceuticals Inc filed Critical Sirtris Pharmaceuticals Inc
Publication of IL219372A0 publication Critical patent/IL219372A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL219372A 2009-10-29 2012-04-23 Bicyclic pyridines and analogs as sirtuin modulators IL219372A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25626909P 2009-10-29 2009-10-29
PCT/US2010/054880 WO2011059839A1 (en) 2009-10-29 2010-10-29 Bicyclic pyridines and analogs as sirtuin modulators

Publications (1)

Publication Number Publication Date
IL219372A0 true IL219372A0 (en) 2012-06-28

Family

ID=43991957

Family Applications (1)

Application Number Title Priority Date Filing Date
IL219372A IL219372A0 (en) 2009-10-29 2012-04-23 Bicyclic pyridines and analogs as sirtuin modulators

Country Status (14)

Country Link
US (1) US9556201B2 (OSRAM)
EP (1) EP2493888B1 (OSRAM)
JP (1) JP2013509442A (OSRAM)
KR (1) KR20120092141A (OSRAM)
CN (1) CN102725291B (OSRAM)
AU (1) AU2010319842A1 (OSRAM)
BR (1) BR112012010010A2 (OSRAM)
CA (1) CA2779303A1 (OSRAM)
ES (1) ES2574927T3 (OSRAM)
IL (1) IL219372A0 (OSRAM)
IN (1) IN2012DN03799A (OSRAM)
MX (1) MX2012004995A (OSRAM)
RU (1) RU2550821C2 (OSRAM)
WO (1) WO2011059839A1 (OSRAM)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA017919B1 (ru) 2007-12-10 2013-04-30 Новартис Аг Производные пиразин-2-карбоксамида для лечения заболеваний, которые поддаются лечению путем блокирования эпителиальных натриевых каналов
KR101679089B1 (ko) 2008-09-29 2016-11-23 서트리스 파마슈티컬즈, 인코포레이티드 시르투인 조절제로서의 크로메논 유사체
CA2869730A1 (en) 2012-04-25 2013-10-31 Takeda Pharmaceutical Company Limited Nitrogenated heterocyclic compound
US9394315B2 (en) 2012-05-08 2016-07-19 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
AU2013259737A1 (en) 2012-05-08 2014-10-02 Lycera Corporation Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
EP2873669A4 (en) 2012-07-13 2015-11-25 Takeda Pharmaceutical HETEROCYCLIC CONNECTION
WO2014033196A1 (en) * 2012-08-30 2014-03-06 F. Hoffmann-La Roche Ag Dioxino- and oxazin-[2,3-d]pyrimidine pi3k inhibitor compounds and methods of use
CN102977117A (zh) * 2012-11-26 2013-03-20 盛世泰科生物医药技术(苏州)有限公司 一种6-溴-2,2-二甲基-2h-吡啶并[3,2-b][1,4]恶嗪-3(4h)-酮的合成方法
GEP201606554B (en) * 2012-12-26 2016-10-10 Takeda Pharmaceuticals Co Nitrogenated heterocyclic compound
US9834520B2 (en) 2013-03-14 2017-12-05 Takeda Pharmaceutical Company Limited Heterocyclic compound
BR112015028613A2 (pt) * 2013-05-13 2017-07-25 Glaxosmithkline Llc análogos de uréia com ligações por pontes substituída como moduladores de sirtuína
WO2016081692A2 (en) * 2014-11-19 2016-05-26 Glaxosmithkline Llc Substituted bridged urea analogs as sirtuin modulators
US10472376B2 (en) 2013-07-03 2019-11-12 Takeda Pharmaceutical Company Limited Amide compound
WO2015002231A1 (ja) 2013-07-03 2015-01-08 武田薬品工業株式会社 複素環化合物
LT3929196T (lt) 2013-09-24 2023-09-25 Fujifilm Corporation Farmacinė kompozicija junginio, kurio sudėtyje yra azotas arba jo druska, arba jo metalo kompleksas
US10172915B2 (en) 2013-10-20 2019-01-08 Duke University Methods and compositions for activation of sirtuins with Annexin A1 peptides
BR112016008276B1 (pt) 2013-10-25 2021-03-02 Novartis Ag derivados bicíclicos de piridila fundidos ao anel, seus usos e seu intermediário, e composição farmacêutica
WO2015095788A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
WO2015095792A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Carbamate benzoxaxine propionic acids and acid derivatives for modulation of rorgamma activity and the treatment of disease
WO2015095795A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
JP6510539B2 (ja) * 2014-01-09 2019-05-08 ザ ジェイ． デヴィッド グラッドストーン インスティテューツ， ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ． デヴィッド グラッドストーン 置換ベンゾオキサジン及び関連化合物
US10532088B2 (en) 2014-02-27 2020-01-14 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
JP2017114764A (ja) * 2014-04-25 2017-06-29 武田薬品工業株式会社 片頭痛治療剤
CA2947290A1 (en) 2014-05-05 2015-11-12 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
US10189777B2 (en) 2014-05-05 2019-01-29 Lycera Corporation Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease
US10316054B2 (en) 2014-06-02 2019-06-11 Glaxosmithkline Intellectual Property (No. 2) Limited Preparation and use of crystalline beta-D-nicotinamide riboside
EP3152220A1 (en) 2014-06-06 2017-04-12 Glaxosmithkline Intellectual Property (No. 2) Limited Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof
ES2756748T3 (es) 2014-10-03 2020-04-27 Novartis Ag Uso de derivados de piridilo bicíclicos de anillo fusionado como inhibidores de fgfr4
KR20170087907A (ko) * 2014-11-19 2017-07-31 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 시르투인 조정제로서의 치환된 가교된 우레아 유사체
US10221142B2 (en) 2015-02-11 2019-03-05 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
EP3292119A4 (en) 2015-05-05 2018-10-03 Lycera Corporation DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE
US10611740B2 (en) 2015-06-11 2020-04-07 Lycera Corporation Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
EP3368516B1 (en) 2015-10-27 2020-07-15 Merck Sharp & Dohme Corp. SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
US10287272B2 (en) 2015-10-27 2019-05-14 Merck Sharp & Dohme Corp. Substituted indazole compounds as RORgammaT inhibitors and uses thereof
CA3002853A1 (en) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
WO2017136727A2 (en) 2016-02-05 2017-08-10 Denali Therapeutics Inc. Compounds, compositions and methods
CN106243045A (zh) * 2016-07-27 2016-12-21 常州大学 一种2,5‑二甲氧基‑4‑氨基嘧啶的制备方法
JOP20190053A1 (ar) * 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
RS63483B1 (sr) 2016-11-08 2022-09-30 Bristol Myers Squibb Co 3-supstituisane propionske kiseline kao inhibitori alfa v integrina
SI3552017T1 (sl) 2016-12-09 2022-09-30 Denali Therapeutics Inc. Spojine uporabne kot zaviralci RIPK1
US9969768B1 (en) 2017-11-16 2018-05-15 King Saud University Oleanolic acid methyl ester derivatives
GB201817047D0 (en) 2018-10-19 2018-12-05 Heptares Therapeutics Ltd H4 antagonist compounds
GB202019667D0 (en) * 2020-12-14 2021-01-27 Heptares Therapeutics Ltd H4 antagonist comnpounds
CN116354937B (zh) * 2021-12-27 2025-07-11 江苏恩华药业股份有限公司 吡啶(嘧啶)胺类衍生物及其应用
CA3245090A1 (en) 2022-01-12 2023-07-20 Denali Therapeutics Inc. CRYSTALLINE FORMS OF (S)-5-BENZYL-N-(5-METHYL-4-OXO-2,3,4,5-TETRAHYDROPYRIDO[3,2-B][L,4]OXAZEPINE-3-YL)-4H-L,2,4-TRIAZOLE-3-CARBOXAMIDE
CN117362286B (zh) * 2023-12-08 2024-03-12 清华大学 具有sirt6激动活性的化合物及其用途

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1108698B (de) 1959-09-03 1961-06-15 Hoechst Ag Verfahren zur Herstellung von 2-(2'-Aminoaryl)-4, 5-arylen-1, 2, 3-triazolen
KR100744893B1 (ko) * 2003-06-20 2007-08-01 에프. 호프만-라 로슈 아게 Ｄｐｐ-ｉｖ 저해제로서 헥사하이드로피리도아이소퀴놀린
EP1828195A2 (en) * 2004-11-23 2007-09-05 PTC Therapeutics, Inc. Substituted phenols as active agents inhibiting vegf production
AU2006218407B2 (en) 2005-03-03 2012-11-15 Sirtris Pharmaceuticals, Inc. Fluorescence polarization assays for acetyltransferase/deacetylase activity
WO2006094210A2 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Tetrahydroquinoxalinone sirtuin modulators
WO2006094235A1 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
EP1856099A2 (en) * 2005-03-03 2007-11-21 Sirtris Pharmaceuticals, Inc. Acridine and quinoline derivatives as sirtuin modulators
WO2006094233A1 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. N,n'-dicyclic isothiourea sirtuin modulators
AU2006218404A1 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. N-phenyl benzamide derivatives as sirtuin modulators
WO2006094248A1 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Aryl-substituted cyclic sirtuin modulators
WO2006094246A2 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. N-arylmethyl benzamide sirtuin modulators
US20070014833A1 (en) 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
EP2805719A1 (en) 2005-03-30 2014-11-26 Glaxosmithkline LLC Nicotinamide riboside and analogues thereof
CA2609549A1 (en) 2005-05-25 2006-11-30 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
DE102005026762A1 (de) * 2005-06-09 2006-12-21 Sanofi-Aventis Deutschland Gmbh Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
JP2009500357A (ja) 2005-07-07 2009-01-08 サートリス ファーマシューティカルズ， インコーポレイテッド 肥満、インスリン抵抗性障害およびミトコンドリア関連障害を処置または予防するための方法および関連する組成物
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
CA2618370A1 (en) 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Oxazolopyridine derivatives as sirtuin modulators
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
EP1955077B1 (en) 2005-12-02 2012-06-13 Sirtris Pharmaceuticals, Inc. Mass spectrometry assays for acetyltransferase/deacetylase activity
JP2009521408A (ja) 2005-12-02 2009-06-04 サートリス ファーマシューティカルズ， インコーポレイテッド Ｃｄｃ２様キナーゼ（ＣＬＫ）のモジュレータおよびその使用方法
DE102006014685A1 (de) * 2006-03-28 2007-10-04 Sanofi-Aventis Imidazo-pyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholiphasen
WO2008027379A2 (en) 2006-08-29 2008-03-06 Sirtris Pharmaceuticals, Inc. Indicators of sirtuin activity and methods of use thereof
WO2008060400A2 (en) 2006-11-15 2008-05-22 Sirtris Pharmaceuticals, Inc. Sirtuin polymorphisms and methods of use thereof
WO2008073451A2 (en) 2006-12-11 2008-06-19 Sirtris Pharmaceuticals, Inc. Benzoimidazole derivatives as sirtuin (sir) modulating compounds
WO2008100423A1 (en) 2007-02-09 2008-08-21 Sirtris Pharmaceuticals, Inc. Gut microsomal triglyceride transport protein inhibitors
WO2008100376A2 (en) 2007-02-15 2008-08-21 Sirtris Pharmaceuticals, Inc. Truncation variants of sirt1 and methods of use thereof
JP2010524432A (ja) 2007-03-19 2010-07-22 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュイン活性のバイオマーカーおよびその使用方法
CL2008001821A1 (es) 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras.
CL2008001822A1 (es) 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
BRPI0819093A2 (pt) 2007-11-01 2017-05-02 Sirtris Pharmaceuticals Inc compostos moduladores de sirtuína
AU2008325148A1 (en) 2007-11-08 2009-05-14 Sirtris Pharmaceuticals, Inc. Solubilized thiazolopyridines
WO2009085226A2 (en) 2007-12-21 2009-07-09 Sirtris Pharmaceuticals, Inc. Inhibitors of cdc2-like kinases (clks) and methods of use thereof
WO2009089011A2 (en) 2008-01-08 2009-07-16 Sirtris Pharmaceuticals, Inc. Resveratrol formulations
CA2723135A1 (en) 2008-05-01 2009-11-05 Sirtris Pharmaceuticals, Inc. Quenolines and related analogs as sirtuin modulators
EP2285977A1 (en) 2008-05-15 2011-02-23 Sirtris Pharmaceuticals, Inc. Sirt1 polymorphic variants and methods of use thereof
EP2297144A1 (en) 2008-05-29 2011-03-23 Sirtris Pharmaceuticals, Inc. Imidazopyridine and related analogs as sirtuin modulators
CN104193740A (zh) 2008-07-03 2014-12-10 西特里斯药业公司 作为沉默调节蛋白调节剂的苯并咪唑类和相关的类似物
KR20110044291A (ko) 2008-08-12 2011-04-28 서트리스 파마슈티컬즈, 인코포레이티드 시르투인 조절제로서의 벤족사졸, 벤즈티아졸 및 관련 유사체
US20110172217A1 (en) 2008-09-05 2011-07-14 Shionogi & Co., Ltd. Ring-fused morpholine derivative having pi3k-inhibiting activity
KR101679089B1 (ko) 2008-09-29 2016-11-23 서트리스 파마슈티컬즈, 인코포레이티드 시르투인 조절제로서의 크로메논 유사체
AU2009314310A1 (en) 2008-10-29 2010-05-20 Sirtris Pharmaceuticals, Inc. Pyridine, bicyclic pyridine and related analogs as sirtuin modulators
WO2010056311A1 (en) * 2008-11-12 2010-05-20 Ariad Pharmaceuticals, Inc. Pyrazinopyrazines and derivatives as kinase inhibitors
CN102307871A (zh) 2008-12-08 2012-01-04 西特里斯药业公司 作为沉默调节蛋白调节剂的异吲哚啉酮和相关的类似物
SG172154A1 (en) 2008-12-16 2011-07-28 Sirtris Pharmaceuticals Inc Phthalazinone and related analogs as sirtuin modulators
UA104447C2 (uk) 2008-12-19 2014-02-10 Сіртріз Фармасьютікалз, Інк. Тіазолопіридинові сполуки, що модулюють сиртуїн
WO2010088574A1 (en) 2009-01-30 2010-08-05 Sirtris Pharmaceuticals, Inc. Azabenzimidazoles and related analogs as sirtuin modulators
BRPI1011477A2 (pt) 2009-03-02 2016-03-22 Sirtris Pharmaceuticals Inc quinolinas 8-substituidas e analogos relacionados como moduladores de sirtuina
CA2773590C (en) * 2009-09-09 2017-09-05 Keiji Adachi 8-oxodihydropurine derivative
WO2011116176A1 (en) 2010-03-17 2011-09-22 Sirtris Pharmaceuticals Inc. 3-substitued imidazo (4, 5-b) pyridines and analogs as sirtuin modulators

Also Published As

Publication number Publication date
EP2493888A1 (en) 2012-09-05
US20120252780A1 (en) 2012-10-04
CA2779303A1 (en) 2011-05-19
EP2493888A4 (en) 2013-05-01
US9556201B2 (en) 2017-01-31
JP2013509442A (ja) 2013-03-14
AU2010319842A1 (en) 2012-05-17
CN102725291A (zh) 2012-10-10
WO2011059839A1 (en) 2011-05-19
CN102725291B (zh) 2016-12-21
RU2012122065A (ru) 2013-12-10
ES2574927T3 (es) 2016-06-23
RU2550821C2 (ru) 2015-05-20
MX2012004995A (es) 2012-10-03
BR112012010010A2 (pt) 2018-03-20
KR20120092141A (ko) 2012-08-20
IN2012DN03799A (OSRAM) 2015-08-28
EP2493888B1 (en) 2016-04-06

Similar Documents

Publication Publication Date Title
IL219372A0 (en) Bicyclic pyridines and analogs as sirtuin modulators
ZA201008380B (en) Imidazopyridine and related analogs as sirtuin modulators
EP2350051A4 (en) PYRIDINE, BICYCLIC PYRIDINE AND ITS ANALOGS AS SIRTUINE MODULATORS
EP2768509A4 (en) SUBSTITUTED BICYCLIC AZA HETEROCYCLES AND ANALOGS AS SIRTUIN MODULATORS
IL214943A0 (en) 8-substituted quinolines and related analogs as sirtuin modulators
EP2768833A4 (en) SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS MODULATORS OF SIRTUINS
IL238849A0 (en) Methods for using c-met modulators
IL208997A0 (en) Quinolines and related analogs as sirtuin modulators
GB2475121B (en) Structure of spraying device
EP2373645A4 (en) ISOINDOLINONE AND RELATED ANALOGUES AS SIRTUIN MODULATORS
IL218770A0 (en) Novel modulators
IL210206A0 (en) Benzimidazoles and related analogs as sirtuin modulators
IL225214A0 (en) Piperidinyl-converted lactams as gpr119 modulators
ZA201209605B (en) Piperidinyl-substituted lactams as gpr119 modulators
EP2768834A4 (en) SUBSTITUTED BICYCLIC AZA HETEROCYCLES AND ANALOGS AS SIRTUIN MODULATORS
GB201709797D0 (en) Novel parasite therapy
GB201004739D0 (en) Receptor modulators
EP2595594A4 (en) MASSAGER
GB201008074D0 (en) Modular bridge
TWM385548U (en) Improved structure of conveyor
TWM372834U (en) Structure of bottle plug
TWM388240U (en) Earring structure
TWM387535U (en) Sock structure for massage teaching
TWM401632U (en) Structure of bottle
TWM387672U (en) Structure of timing micro-capsule